

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – May 13, 2020 @ 4:00pm

OHCA Webinar

Register for the meeting here:

https://okhca.zoom.us/webinar/register/WN_2R6cQO1gT5afVrf5eeV2ww

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Skrepnek

Telephone Conference Participants

DUR Board Members:

Dr. Megan Hanner -	participating via Zoom Teleconference
Dr. Markita Broyles -	participating via Zoom Teleconference
Dr. Stephen Anderson -	participating via Zoom Teleconference
Dr. Theresa Garton -	participating via Zoom Teleconference
Dr. John Muchmore -	participating via Zoom Teleconference
Dr. James Osborne -	participating via Zoom Teleconference
Dr. Lynn Mitchell -	participating via Zoom Teleconference
Ms. Jennifer Boyett -	participating via Zoom Teleconference
Dr. Lee Munoz -	participating via Zoom Teleconference
Dr. Jennifer De Los Angeles -	participating via Zoom Teleconference

Public Access to Meeting via Zoom:

Register at: https://okhca.zoom.us/webinar/register/WN_2R6cQO1gT5afVrf5eeV2ww

Or join by phone:

+1 346 248 7799 (US Toll) or +1 669 900 6833 (US Toll)

Webinar ID: 947 7528 2930

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting www.okhca.org/DUR and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

A. Acknowledgment of Speakers Registered for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. March 11, 2020 DUR Minutes – Vote
- B. March 11, 2020 DUR Recommendations Memorandum
- C. April 8, 2020 DUR Recommendations Memorandum

Items to be presented by Dr. Adams, Dr. Van, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Pipeline Update – See Appendix B

- A. Pharmacy Helpdesk Activity for April 2020
- B. Medication Coverage Activity for April 2020
- C. Spring 2020 Pipeline Update

Items to be presented by Dr. Van, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Katerzia™ (Amlodipine Oral Suspension) and Conjupri® (Levamlodipine Tablet) – See Appendix C

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Tepezza™ (Teprotumumab-trbw) – See Appendix D

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Dayvigo™ (Lemborexant) – See Appendix E

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Mayzent® (Siponimod), Mavenclad® (Cladribine), and Vumerity® (Diroximel Fumarate) – See Appendix F

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Qternmet® XR [Dapagliflozin/Saxagliptin/Metformin Extended-Release (ER) Tablet], Riomet ER™ (Metformin ER Oral Suspension), Rybelsus® (Semaglutide Tablet), and Trijardy™ XR (Empagliflozin/Linagliptin/Metformin ER Tablet) and Update the Anti-Diabetic Medications Prior Authorization Criteria – See Appendix G

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Ayvakit™ (Avapritinib), Bynfezia Pen™ (Octreotide), and Tazverik™ (Tazemetostat) – See Appendix H

- A. Introduction
- B. Product Summaries
- C. Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Aliqopa™ (Copanlisib), Brukinsa™ (Zanubrutinib), Polivy™ (Polatuzumab Vedotin-piiq), and Ruxience™ (Rituximab-pvvr) – See Appendix I

- A. Introduction
- B. Product Summaries
- C. Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Muchmore, Chairman:

12. Action Item – Vote to Prior Authorize Pemfexy™ (Pemetrexed), Rozlytrek® (Entrectinib), and Zirabev™ (Bevacizumab-bvzr) – See Appendix J

- A. Introduction
- B. Product Summaries
- C. Recommendations

Non-Presentation Item; Questions Only:

13. Annual Review of Balversa™ (Erdafitinib) – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Balversa™ (Erdafitinib)
- C. Prior Authorization of Balversa™ (Erdafitinib)
- D. Market News and Updates
- E. Recommendations

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

14. Annual Review of the SoonerCare Pharmacy Benefit – See Appendix L

- A. Summary
- B. Medicaid Drug Rebate Program
- C. Alternative Payment Models
- D. Drug Approval Trends
- E. Traditional Versus Specialty Pharmacy Products
- F. Top 10 Therapeutic Classes by Reimbursement
- G. Top 10 Medications by Reimbursement
- H. Cost Per Claim
- I. Conclusion
- J. Top 50 Reimbursed Drugs by Fiscal Year
- K. Top 50 Medications by Total Number of Claims
- L. Top 10 Traditional and Specialty Therapeutic Categories by Fiscal Year

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

15. Annual Review of Granulocyte Colony-Stimulating Factors (G-CSFs) and 30-Day Notice to Prior Authorize Ziextenzo® (Pegfilgrastim-bmez) – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of G-CSFs
- C. Prior Authorization of G-CSFs
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of G-CSFs

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

16. Annual Review of Allergen Immunotherapies and 30-Day Notice to Prior Authorize Palforzia™ (Peanut Allergen Powder-dnfp) – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Allergen Immunotherapies
- C. Prior Authorization of Allergen Immunotherapies
- D. Market News and Updates
- E. Palforzia™ (Peanut Allergen Powder-dnfp) Product Summary
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

17. Annual Review of Parkinson's Disease (PD) Medications and 30-Day Notice to Prior Authorize Nourianz™ (Istradefylline) – See Appendix O

- A. Current Prior Authorization Criteria
- B. Utilization of PD Medications
- C. Prior Authorization of PD Medications
- D. Market News and Updates
- E. Nourianz™ (Istradefylline Tablet) Product Summary

- F. College of Pharmacy Recommendations
- G. Utilization Details of PD Medications

Items to be presented by Dr. Van, Dr. Muchmore, Chairman:

18. Action Item – Annual Review of Idiopathic Pulmonary Fibrosis (IPF) Medications – See Appendix P

- A. Current Prior Authorization Criteria
- B. Utilization of IPF Medications
- C. Prior Authorization of IPF Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of IPF Medications

Non-Presentation Item; Questions Only:

19. Annual Review of Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase) – See Appendix Q

- A. Current Prior Authorization Criteria
- B. Utilization of Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase)
- C. Prior Authorization of Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase)
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

20. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix R

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

21. Future Business* (Upcoming Product and Class Reviews)

- A. Attention deficit/hyperactivity disorder (ADHD) and Narcolepsy Medications
- B. Atypical Antipsychotic Medications
- C. Various Special Formulations
- D. Ophthalmic Anti-Inflammatories

**Future business subject to change.*

22. Adjournment